Can histologic features predict neoadjuvant therapy response in rectal adenocarcinoma?

Area of Science:

• Oncology
• Surgical Pathology

Background:

• Standard treatment for locally advanced rectal cancer (LARC) involves neoadjuvant therapy followed by surgery.
• Patient response to neoadjuvant therapy for LARC is highly variable.
• Predicting treatment response is crucial for optimizing patient outcomes.

Purpose of the Study:

• To identify specific histologic features in pre-treatment biopsies that predict tumor response to neoadjuvant therapy in LARC patients.
• To evaluate the correlation between various biopsy-based histologic factors and tumor regression after neoadjuvant treatment.

Main Methods:

• Retrospective analysis of 105 LARC patients who underwent biopsy, neoadjuvant therapy, and surgical resection.
• Evaluation of biopsy samples for 14 histologic features including tumor grade, budding, lymphocytes, neutrophils, desmoplasia, apoptosis, signet ring cells, mucinous features, Paneth cells, necrosis, ulceration, and lymphoid aggregates.
• Comparison of histologic findings with tumor regression grades from resection specimens, alongside patient age and microsatellite status.

Main Results:

• No statistically significant association was found between any of the evaluated histologic features in pre-therapy biopsies and the degree of tumor response observed in post-therapy resection specimens.
• The study did not identify any reliable biopsy-based histologic predictors of neoadjuvant therapy response in LARC.

Conclusions:

• Histologic features assessed in pre-therapy biopsies of locally advanced rectal cancer do not reliably predict subsequent response to neoadjuvant therapy.
• The development of effective and dependable methods for predicting neoadjuvant therapy response in rectal cancer remains an unmet clinical need.